Nasal Epithelial Organoids as Translational Platforms in Inflammatory, Infectious, and Precision Medicine Applications: A Systematic Review Authors: Veronica Scocca, Lorenzo Lauda, Riccardo Nocini, Giovanni Dell’Aversana Orabona Published: 2026 ABSTRACT Background/Objectives: The airway epithelium plays a central role in host defense, inflammatory signaling, and disease progression across infectious, inflammatory, and genetic respiratory disorders. Human nasal epithelial organoids have emerged as accessible and patient-specific in vitro platforms with increasing translational relevance. This systematic review aimed to critically evaluate the current evidence on nasal epithelial organoid models, focusing on donor characteristics, culture methodologies, differentiation strategies, and translational applications. Methods: A systematic search of PubMed/MEDLINE, Embase, Scopus, Ovid MEDLINE, and Cochrane Library was conducted for studies published between 1990 and April 2026. The review followed PRISMA guidelines and was structured according to the PICOTS framework. Eligible studies included in vitro experimental investigations using human-derived nasal epithelial organoids in infectious, inflammatory, or precision medicine contexts. Risk of bias was assessed using the QUIN tool. Results: Seventeen studies met the inclusion criteria. Applications clustered into three principal domains: infectious disease modeling, inflammatory and epithelial remodeling research, and cystic fibrosis precision medicine. Most studies employed expandable three-dimensional Matrigel-embedded organoids or organoid-derived air–liquid interface systems. Infection-focused studies demonstrated variant-specific viral replication dynamics and epithelial immune responses, while inflammatory models reproduced disease-associated differentiation and remodeling phenotypes. Cystic fibrosis oriented studies showed that organoid swelling and electrophysiological assays correlate with CFTR functional rescue and, in selected cases, clinical response. Methodological heterogeneity across protocols and outcome reporting precluded quantitative synthesis. Conclusions: Human nasal epithelial organoids represent versatile translational platforms bridging accessible patient-derived tissue and advanced airway disease modeling. Although variability in culture protocols and functional benchmarks limits standardization, these models hold significant promise for mechanistic investigation, therapeutic stratification, and precision medicine applications. 1. Introduction Chronic respiratory diseases and airway infections remain among the leading causes of global morbidity and mortality, imposing an escalating socioeconomic burden worldwide [1,2]. At the forefront of respiratory defense lies the airway epithelium, a highly specialized and dynamic tissue that integrates barrier integrity, mucociliary clearance, and finely tuned innate immune responses. Beyond functioning as a passive structural interface, the epithelium actively orchestrates host–pathogen interactions, inflammatory signaling cascades, and tissue remodeling processes that critically shape disease onset and progression [3,4,5,6]. Mounting evidence indicates that epithelial dysfunction is not merely a consequence but a central driver of airway pathology, contributing to chronic rhinosinusitis, asthma, chronic obstructive pulmonary disease, cystic fibrosis, and emerging viral infections [7,8,9,10]. However, mechanistic dissection of epithelial biology has historically relied on animal models and immortalized cell lines, both limited by interspecies divergence, altered differentiation states, and incomplete recapitulation of native airway architecture [11,12,13]. These constraints have hindered translational extrapolation and the development of precision therapeutic strategies. Primary human airway epithelial models have transformed the landscape of respiratory research by preserving donor-specific molecular signatures and functional phenotypes [14,15]. In particular, human nasal epithelial cells (hNECs) offer a unique translational advantage: they are accessible through minimally invasive sampling, amenable to longitudinal collection, and share structural, transcriptomic, and immunological features with lower airway epithelia [16,17,18,19]. This has positioned nasal-derived systems as robust surrogates for bronchial tissue, enabling scalable and patient-specific modeling of airway disease. Technological advances have further propelled the field. Air–liquid interface (ALI) cultures permit differentiation into pseudostratified mucociliary epithelia with functional barrier properties [20,21,22], while three-dimensional organoid systems recapitulate epithelial self-organization, cellular heterogeneity, and disease-specific phenotypes in a spatially structured context [23,24]. These platforms have been successfully applied to model viral tropism and persistence, inflammatory remodeling, and CFTR-dependent functional rescue, underscoring their relevance for both mechanistic investigation and therapeutic stratification [25,26,27,28]. Despite this rapid expansion, methodological heterogeneity and variable reporting standards complicate interpretation and comparison across studies. A critical synthesis of available evidence is therefore essential to define the current state of nasal epithelial organoid research, identify translational strengths and limitations, and delineate future directions. Accordingly, this systematic review aims to comprehensively evaluate human nasal epithelial organoid models, focusing on donor characteristics, culture methodologies, differentiation strategies, and translational applications across infectious, inflammatory, and precision medicine domains. 2. Materials and Methods The study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Table S1). Since it involved a review of previously published studies, neither ethics approval nor informed consent were required. The review was prospectively registered in the PROSPERO database (ID: 1363878) during the early phase of the study, prior to completion of data extraction. In light of the exploratory scope and methodological heterogeneity characteristic of preclinical organoid research, the PROSPERO registration was intended to ensure transparency of objectives, eligibility criteria, and methodological framework, rather than to predefine rigid analytic procedures. No additional standalone protocol was developed beyond the registered record. 2.1. Search Strategy The research covered the years 1990–2026 and included Pubmed/MEDLINE, Cochrane Library, Scopus, Ovid MEDLINE, and EMBASE databases. The broad temporal window was intentionally selected to capture potential early precursor technologies; however, all eligible studies were published between 2020 and 2026, reflecting the recent emergence of nasal epithelial organoid platforms. Relevant keywords, phrases and MeSH terms were tailored to meet the specific requirements of each individual database. An example of the search strategy used for PubMed/MEDLINE was: (“nasal organoids”[Title/Abstract] OR “nasal epithelial organoids”[Title/Abstract] OR “nasal epithelial cells”[Title/Abstract] OR “nasal epithelium”[Title/Abstract]) AND (“inflammatory sinonasal disease”[Title/Abstract] OR “chronic rhinosinusitis”[Title/Abstract] OR “CRS”[Title/Abstract] OR “sinonasal inflammation”[Title/Abstract] OR “respiratory infection”[Title/Abstract] OR “viral infection”[Title/Abstract] OR “bacterial infection”[Title/Abstract] OR “host–pathogen interaction”[Title/Abstract] OR “immune response”[Title/Abstract]). Medical Subject Headings (MeSH) terms were incorporated where appropriate, including “Organoids,” “Nasal Mucosa,” “Rhinitis,” “Sinusitis,” and “Respiratory Tract Infections.” The initial search was conducted on 2 April 2026. An updated search was subsequently performed on 30 April 2026 using expanded terminology to increase sensitivity and capture heterogeneous nomenclature within the field. Additional keywords included “spheroids,” “apical-out organoids,” “airway organoids,” and “HNEC-derived models.” No additional eligible studies were identified following full-text screening. A manual cross-reference search of the selected articles was subsequently performed using the snowballing method to ensure comprehensive identification of all relevant studies. 2.2. Study Selection This systematic review was conducted according to the PICOTS framework. Patients (P) The population of interest included human-derived nasal epithelial cells obtained from both healthy donors and patients affected by inflammatory, infectious, or genetically mediated epithelial disorders affecting the sinonasal mucosa. Inflammatory conditions included chronic rhinosinusitis with or without nasal polyps and allergic rhinitis, while infectious conditions comprised viral, bacterial, and fungal sinonasal infections. Both adult and pediatric populations were considered eligible. Intervention (I) The intervention consisted of the generation and application of nasal epithelial organoids as experimental and translational platforms. Studies evaluating primary three-dimensional nasal epithelial organoid cultures as well as organoid-derived differentiated systems (including air–liquid interface configurations) were included, provided that nasal-specific data were clearly extractable. Experimental models assessing inflammatory stimulation, host–pathogen interactions, infection dynamics, therapeutic testing, drug-response profiling, or advanced molecular analyses such as transcriptomics, proteomics, or gene editing were considered eligible. Comparison (C) When available, comparisons included organoids derived from diseased versus healthy donors, infected versus non-infected conditions, stimulated versus unstimulated models, treated versus untreated samples, and three-dimensional organoid cultures versus conventional two-dimensional systems. Studies comparing nasal organoids with other airway-derived organoids were included only when nasal-specific data could be clearly extracted. Outcomes (O) Outcomes were categorized as primary and secondary according to the experimental domain and translational intent of each study. Primary outcomes included structural and functional epithelial endpoints directly related to model validation and disease-specific investigation. These comprised morphological and phenotypic characterization of the differentiated epithelium (e.g., lumen formation, presence of ciliated, goblet, basal, and ionocyte populations), assessment of epithelial barrier integrity, ciliary activity, and disease-relevant functional metrics such as CFTR activity or pathogen replication dynamics. In infection-focused studies, primary outcomes included viral or bacterial replication kinetics, multiplicity of infection (MOI) when reported, and time-dependent epithelial responses. In inflammatory and remodeling investigations, primary outcomes included epithelial differentiation patterns, extracellular matrix-dependent changes, and modulation of inflammatory signaling pathways. Secondary outcomes included immune response profiling (e.g., cytokine and chemokine production), transcriptomic or proteomic analyses, therapeutic response assessment, drug responsiveness testing, and comparative benchmarking between different organoid configurations or culture systems. Translational relevance was evaluated based on the capacity of each model to reproduce disease-specific mechanisms, host–pathogen interactions, and treatment responsiveness in a reproducible and biologically coherent manner. Timing (T) No restrictions were applied regarding experimental timepoints, and both short-term and long-term organoid culture studies were included. Study design (S) Eligible study designs comprised in vitro experimental studies and translational laboratory investigations involving nasal epithelial organoids. Conference abstracts, editorials, letters to the editor, book chapters, and narrative reviews were excluded. Studies were also excluded if they did not specifically involve nasal epithelial organoids or if nasal-specific data could not be clearly extracted. Mixed-cohort studies including multiple airway organoid types were considered eligible only when results specific to nasal organoids were separately reported. 2.3. Data Collection Process The search was conducted independently by two investigators (V.S. and G.D.A.O.). References from the identified databases were merged, and duplicates were removed using the reference management software EndNote® 21 (version 21.5). Articles were screened for relevance based on title and abstract, with those deemed appropriately selected for full-text review. Any discrepancies between the screening authors were resolved through discussion until consensus was reached. Systematic data extraction from the included studies was made using a structured form, with data archived in a customized Excel® (Microsoft Corp, Seattle, WA, USA) spreadsheet. One author (V.S.) independently extracted the relevant study characteristics, including title, authors, year of publication, model type, application, main outcomes assessed, key findings, limitations, translational relevance, donor characteristics, sample collection methods, organoid generation protocol, differentiation protocol (including air–liquid interface when applicable), final epithelial phenotype, multiplicity of infection (MOI), and experimental timepoints. The accuracy of the extracted data was verified by another author (G.D.A.O.). 2.4. Data Synthesis and Analysis Due to the anticipated methodological heterogeneity across studies, including differences in organoid generation protocols, donor characteristics, inflammatory or infectious models, experimental endpoints, and outcome reporting, a primarily qualitative synthesis was performed. The findings of the included studies were systematically summarized according to the predefined extraction domains, including application, biological and functional outcomes, immune response profiling, pathogen interaction dynamics, and translational relevance. Given the experimental nature of most included studies, variability in multiplicity of infection (MOI), timepoints, differentiation protocols, and phenotypic endpoints was carefully examined and reported descriptively. Subgroup analyses were planned according to disease category (inflammatory versus infectious), organoid culture system (submerged versus air–liquid interface), and translational application (mechanistic modeling versus therapeutic testing), when sufficient data were available. Risk of bias was assessed using the Quality In Non-randomized Studies (QUIN) tool [29]. The tool was adapted to the context of in vitro experimental studies involving nasal epithelial organoids. Six methodological domains were evaluated: (i) clarity of study objectives; (ii) donor characterization and metadata transparency; (iii) organoid generation and matrix reporting; (iv) validation of epithelial differentiation and phenotype; (v) completeness of functional outcome reporting; and (vi) statistical transparency and reproducibility. Each study was categorized as low, moderate, or high risk of bias based on the overall methodological quality. 3. Results 3.1. Study Selection A total of 457 records were identified through database searching (PubMed n = 143, Embase n = 150, Scopus n = 73, Ovid MEDLINE n = 87, and Cochrane Library n = 4). After removal of 311 duplicate records, 146 unique articles remained for title and abstract screening. Of these, 109 records were excluded based on irrelevance to the study objectives. Thirty-seven reports were sought for full-text retrieval. Seven reports could not be retrieved, resulting in 30 full-text articles assessed for eligibility. During full-text evaluation, 13 studies were excluded for the following reasons: not organoid-based (n = 3), not exclusively nasal-derived (n = 3), not published in English (n = 1), inappropriate study design (n = 3), duplicate cohort (n = 1), comment article (n = 1), and book series (n = 1). Seventeen studies met the predefined inclusion criteria and were included in the qualitative synthesis. The study selection process is described in Figure 1. 3.2. Description of the Studies The general characteristics of the included studies are summarized in Table 1. To reduce conceptual heterogeneity and facilitate interpretive synthesis, included studies were analytically stratified into three domains: (i) mechanistic infection models, (ii) inflammatory and epithelial remodeling investigations, and (iii) translational precision medicine platforms, primarily focused on CFTR functional assessment. This stratification guided both the qualitative synthesis and the subsequent discussion of methodological maturity. All included articles were published in English between 2020 and 2026, reflecting the recent and rapidly expanding interest in nasal epithelial organoids as translational research platforms. The majority of studies were experimental in vitro investigations using patient-derived nasal epithelial cells, with a predominance of three-dimensional organoid cultures and air–liquid interface (ALI) differentiation systems. 3.2.1. Mechanistic Infection Models A substantial proportion of studies focused on infectious disease modeling. Viral infection models were investigated by Aloisio et al. [32,36], Chiu et al. [40], Li C. et al. [38], Wan et al. [34], and Zhu et al. [35], primarily evaluating SARS-CoV-2 and respiratory syncytial virus (RSV) replication dynamics, epithelial immune responses, and variant-specific infectivity. Bacterial colonization and host–microbiota interactions were explored by Boyd et al. [33]. Together, these studies demonstrated the suitability of nasal organoids for modeling upper airway host–pathogen interactions and epithelial inflammatory responses. 3.2.2. Inflammatory and Epithelial Remodeling Investigations Inflammatory and epithelial remodeling mechanisms were addressed by Ramezanpour et al. [42] and Li L. et al. [37], who investigated chronic rhinosinusitis-derived organoids and extracellular matrix-dependent differentiation pathways, respectively. Ramezanpour et al. [31] further compared different in vitro nasal epithelial culture systems, highlighting the translational relevance of apical-out organoid configurations. These studies emphasized structural and differentiation fidelity rather than pathogen interaction, highlighting matrix composition and polarity configuration as biologically relevant determinants. 3.2.3. Translational Precision Medicine Platforms Precision medicine and CFTR functional assessment constituted another major area of application. Liu et al. [10,41], Anderson et al. [44], Sette et al. [45], Rodenburg et al. [43], Amatngalim et al. [39], and Borek-Dohalska et al. [30] evaluated CFTR function, drug responsiveness, and theratyping strategies using nasal epithelial organoids. These studies demonstrated the utility of organoid swelling assays, electrophysiological measurements, and genotype-specific drug response profiling as patient-specific biomarkers for therapeutic stratification. Within this domain, functional standardization was more advanced compared to infection and inflammatory studies, with reproducible swelling assays and electrophysiological benchmarking frequently reported. The relative distribution of functional validation across model configurations and application domains is summarized in Figure 2. 3.3. Model Type The included studies demonstrated considerable variability in nasal epithelial organoid model configurations, reflecting the evolving methodological landscape of the field. Most investigations employed patient-derived three-dimensional (3D) organoid cultures generated from nasal brushings or swabs and expanded in extracellular matrix-based systems, predominantly Matrigel. Foundational expandable 3D nasal organoid platforms were described by Liu et al. [10,41], Anderson et al. [44], Rodenburg et al. [43], and Amatngalim et al. [39], which established reproducible lumen-forming structures suitable for functional CFTR assessment and translational drug testing. Several studies implemented ALI differentiation systems derived from 3D-expanded organoids or directly from stem-cell-enriched epithelial populations. Aloisio et al. [32,36] and Chiu et al. [40] utilized human nasal organoid–ALI (HNO-ALI) platforms to model respiratory viral infections, generating pseudostratified mucociliary epithelia with functional ciliated, goblet, and basal cell populations. Similarly, Boyd et al. [33] employed ALI-differentiated nasal organoids to investigate bacterial colonization dynamics, while Wan et al. [34], and Li C. et al. [38] adapted differentiated organoid monolayers for SARS-CoV-2 infectivity and neutralization assays. Innovative structural configurations were also reported. Li L. et al. [37] developed apical-out nasal organoids embedded in a collagen–alginate–hyaluronic acid hydrogel system to model extracellular matrix–epithelium interactions, whereas Ramezanpour et al. [31] comparatively evaluated dome organoids, ALI organoids, and monolayer cultures, identifying apical-out ALI organoids as the model most closely resembling in vivo nasal proteomic profiles. Ramezanpour et al. [42] generated expandable chronic rhinosinusitis-derived organoids embedded in Matrigel, providing a disease-specific 3D model. Comparative airway models were included when nasal-specific data were clearly extractable. Zhu et al. [35] analyzed paired nasal and bronchial organoids derived from the same donors, enabling region-specific immune comparisons. Borek-Dohalska et al. [30] combined nasal epithelial ALI cultures with intestinal organoids for CFTR modulator comparison, though nasal-specific outcomes were distinctly reported. Overall, the predominant model types comprised (i) expandable 3D Matrigel-embedded nasal organoids, (ii) organoid-derived ALI differentiated monolayers, and (iii) apical-out hydrogel-based systems. Despite methodological heterogeneity in expansion media, differentiation duration, and extracellular matrix composition, the majority of models consistently recapitulated key features of the human mucociliary nasal epithelium, supporting their translational applicability. 3.4. Donor Population The donor populations included in the selected studies were heterogeneous and reflected the broad translational scope of nasal epithelial organoid research. Several investigations utilized healthy adult donors for infection modeling and baseline epithelial characterization [32,33,34,38,40]. These studies primarily focused on viral or bacterial infection dynamics and epithelial immune responses in physiologically differentiated mucociliary models. Pediatric donors were specifically represented in infection-focused studies. Zhu et al. [35] employed paired nasal and bronchial organoids derived from pediatric subjects, while Aloisio et al. [36] compared infant-derived nasal organoids with those from older donors, demonstrating age-dependent differences in viral susceptibility and inflammatory responses. Disease-specific cohorts were included in inflammatory and remodeling investigations. Ramezanpour et al. [42] generated organoids from chronic rhinosinusitis (CRS) patients, while Ramezanpour et al. [31] included both CRS patients and non-CRS controls for comparative model evaluation. Li L. et al. [37] established apical-out nasal organoids from surgical specimens of CRS patients to investigate extracellular matrix-dependent differentiation mechanisms. A substantial proportion of studies [10,30,39,41,43,44,45] focused on cystic fibrosis (CF) populations to assess CFTR function and precision medicine applications, and incorporated genotype-stratified CF cohorts, including F508del homozygous and compound heterozygous mutations, as well as non-CF controls in selected studies. 3.5. Organoid Generation Across the included studies, nasal epithelial organoids were predominantly generated from minimally invasive nasal brushings or swab-derived epithelial cells, followed by stem cell expansion and three-dimensional (3D) culture in extracellular matrix-based systems. Foundational expandable Matrigel-embedded organoid platforms were described by those studies [10,39,41,43,44], in which primary human nasal epithelial cells were expanded—often using conditional reprogramming culture (CRC) or feeder-based systems—and subsequently embedded in high-concentration Matrigel to promote lumen-forming 3D spheroids. In infection-focused studies [32,33,34,36,38,40], basal epithelial stem cells were expanded and embedded in Matrigel prior to differentiation. These protocols typically involved enzymatic digestion of nasal samples, debris removal, and short-term 3D expansion before downstream differentiation or infection assays. Innovative variations in extracellular matrix composition were introduced by Li L. et al. [37], who developed a collagen I–alginate–hyaluronic acid hydrogel system to generate apical-out nasal organoids, thereby enabling investigation of matrix-dependent epithelial remodeling. Similarly, Ramezanpour et al. [31,42] generated disease-specific organoids from CRS and control donors using Matrigel embedding and comparative expansion strategies. Overall, although matrix composition, seeding density, and expansion duration varied among studies, most protocols shared a common framework of primary nasal epithelial isolation, stem/progenitor cell enrichment, and 3D embedding to establish expandable organoid cultures (Figure 3). The methodological and experimental features of the included models are summarized in Table 2. 3.6. Differentiation Protocols Following 3D expansion, differentiation strategies varied depending on the intended translational application. A substantial number of studies [32,33,34,36,38,40] employed ALI differentiation systems to generate pseudostratified mucociliary epithelium. This approach was central to viral and bacterial infection models, where organoids were dissociated into single cells and seeded onto transwell inserts prior to apical air exposure. Differentiation typically occurred over approximately 21 days, resulting in multicellular epithelia containing ciliated, goblet, basal, and secretory cell populations. In contrast, several CF-focused studies [10,30,39,41,43,44] retained fully 3D submerged organoid configurations for functional assays, particularly forskolin-induced swelling (FIS) analyses. These models demonstrated spontaneous epithelial differentiation within Matrigel, achieving functional maturity typically by day 21. Alternative differentiation configurations were explored in selected studies. Li L. et al. [37] established apical-out polarity during hydrogel-based differentiation, while Ramezanpour et al. [31] comparatively evaluated dome organoids, ALI monolayers, and apical-out ALI organoids, identifying the latter as most closely resembling in vivo nasal epithelial proteomic profiles. Collectively, despite variability in medium composition, duration, and polarity orientation, the majority of differentiation protocols successfully generated mucociliary epithelial phenotypes suitable for modeling infection, inflammation, barrier function, and precision medicine applications. 3.7. Translational Relevance The included studies collectively demonstrate that nasal epithelial organoids represent a versatile and physiologically relevant translational platform bridging basic epithelial biology and clinically meaningful applications. In the context of infectious disease modeling, organoid-derived air–liquid interface systems were shown to recapitulate upper airway viral tropism, epithelial injury, and strain-specific immune responses. These studies [32,34,35,36,38,40] demonstrated the capacity of nasal organoids to model SARS-CoV-2 and RSV replication dynamics, variant-specific infectivity, cytokine responses, and age-dependent susceptibility. These findings highlight the suitability of nasal organoids as human-relevant alternatives to immortalized cell lines and animal models for studying host–pathogen interactions and evaluating antiviral strategies. In inflammatory and remodeling contexts [31,37,42] demonstrated that nasal organoids can reproduce disease-associated epithelial phenotypes, extracellular matrix-dependent differentiation processes, and mucociliary functional alterations. These platforms provide mechanistic insight into epithelial barrier dysfunction and remodeling pathways relevant to chronic rhinosinusitis and other inflammatory airway disorders. Precision medicine applications were particularly evident in cystic fibrosis-focused studies [10,30,39,41,43,44,45], which demonstrated that nasal organoid swelling assays and electrophysiological measurements correlate with CFTR functional rescue and, in selected studies, with clinical treatment response. These findings support the use of nasal organoids as patient-specific theratyping tools and potential surrogate biomarkers for drug responsiveness, particularly in rare genotypes. Importantly, nasal epithelial organoids are derived from minimally invasive sampling procedures, enabling repeated longitudinal sampling and personalized modeling. While limitations remain—including absence of immune and stromal compartments, donor variability, and protocol heterogeneity—the cumulative evidence supports nasal organoids as scalable, human-derived platforms with strong translational potential across infectious, inflammatory, and precision medicine domains. 3.8. Risk of Bias Assessment Risk of bias was evaluated using the QUIN tool across six methodological domains. Overall, the included studies demonstrated acceptable methodological quality. Most investigations were classified as low risk of bias for clarity of study objectives and completeness of outcome reporting. Donor characterization showed greater variability, with several studies providing limited demographic or clinical metadata, resulting predominantly in moderate risk assessments in this domain. Organoid generation protocols were generally well described, although differences in reporting depth were observed. Experimental controls and statistical analyses were typically adequate but not uniformly standardized, leading mainly to moderate risk classifications. No study was judged to have consistently high risk of bias across multiple domains. Methodological limitations were largely related to small sample sizes and incomplete reporting rather than fundamental design weaknesses. The detailed domain-level assessment is presented in Figure 4. 4. Discussion This systematic review synthesizes the current landscape of human nasal epithelial organoid and advanced hNEC-derived models, highlighting their rapid transition from descriptive in vitro systems to translationally oriented platforms. Across applications, a clear gradient of translational maturity emerges. Cystic fibrosis-focused models demonstrate greater methodological standardization and functional benchmarking, whereas infectious and inflammatory applications remain more heterogeneous in terms of differentiation protocols, experimental readouts, and reporting standards. This imbalance has implications for reproducibility and clinical translatability. A central observation emerging from this review is that nasal epithelial systems have moved beyond their original role as surrogate models of bronchial epithelium. Their accessibility, combined with preservation of donor-specific molecular and functional traits, positions them as uniquely suited for longitudinal sampling and precision-oriented investigation. Within the broader “one airway” framework [14,15], nasal models are no longer merely convenient alternatives but increasingly serve as biologically meaningful proxies in defined mechanistic contexts. However, the field remains methodologically fragmented. Substantial variability persists in expansion protocols, differentiation timelines, extracellular matrices, and functional assays. Matrix composition (e.g., Matrigel versus defined hydrogel systems), differentiation duration (14 versus 21–28 days), and polarity configuration (apical-in versus apical-out) are not merely technical variables but determinants of epithelial maturation, barrier properties, and functional readouts. Similarly, organoid-derived ALI systems and directly differentiated ALI monolayers may exhibit divergent transcriptomic and proteomic fidelity. These differences significantly influence cross-study comparability and interpretation of translational validity. Such methodological divergence directly affects epithelial phenotype, barrier integrity, and ion transport measurements, thereby influencing translational inference. Importantly, upstream expansion strategy can shape downstream functional readouts, raising concerns regarding cross-study comparability. The absence of standardized quality benchmarks—whether transcriptomic fidelity thresholds, minimal transepithelial resistance values, or defined differentiation criteria—represents a critical barrier to reproducibility [20,24,28]. Even when similar readouts are employed (e.g., FIS assays, cytokine panels, viral replication kinetics), variations in expansion strategies, differentiation duration, and matrix composition may substantially affect outcome magnitude, thereby limiting external validity. Another important conceptual shift concerns the increasing use of organoid configurations to interrogate epithelial polarity and host–pathogen interactions. Apical-out systems, in particular, reflect a methodological refinement that addresses limitations of traditional 3D cultures. Yet even these advances highlight a persistent limitation: most systems remain epithelial monocultures. While this reductionist approach enables controlled mechanistic interrogation, it does not fully capture epithelial–immune crosstalk, stromal signaling, or vascular contributions that shape airway pathology in vivo. The integration of immune components into co-culture or microfluidic systems will likely represent the next meaningful step toward physiological complexity [22,23]. From a translational perspective, the most mature application currently lies in cystic fibrosis modeling, where functional assays have enabled patient-specific drug testing [44]. In contrast, inflammatory and infectious disease applications, although mechanistically informative, are still limited by variability in infection protocols, multiplicity of infection, and cytokine exposure paradigms. Moreover, many infectious studies rely on limited donor numbers and lack integrated immune or stromal components, warranting cautious interpretation of translational claims. The heterogeneity observed across studies suggests that translational standardization has not yet kept pace with technological innovation. Donor variability presents a dual-edged phenomenon. On one hand, it introduces experimental noise and complicates reproducibility. On the other, it preserves biologically meaningful interindividual differences that may underlie disease susceptibility and therapeutic response [16,19]. The method of tissue procurement (e.g., brushings, swabs, or surgical specimens) may further influence initial cellular composition and expansion dynamics, yet this variable remains insufficiently analyzed across studies. Future strategies will need to balance standardization with preservation of this intrinsic biological diversity, potentially through structured biobanking initiatives and harmonized metadata reporting. Finally, structural constraints remain. The reliance on basement membrane extracts introduces batch-dependent variability. Long-term stability of differentiated cultures can be inconsistent. Moreover, the absence of vascularization and systemic influences limits modeling of chronic disease evolution. Addressing these limitations will require integration of defined synthetic matrices, organ-on-chip technologies, and multi-omic profiling approaches capable of validating in vitro fidelity against in vivo benchmarks. Overall, nasal epithelial organoid systems are transitioning from promising experimental tools to platforms with genuine translational ambition. Yet their future impact will depend less on incremental technological refinement and more on the establishment of standardized methodological frameworks, inter-laboratory validation, and functional benchmarking. The field is now mature enough to demand rigor, not just innovation. A central question emerging from this review is whether a single “best” methodological configuration can be defined. Our analysis suggests that model suitability is inherently application-dependent. For infectious disease modeling, ALI-differentiated systems appear optimal due to accessible apical surfaces, preserved mucociliary architecture, and reproducible viral entry dynamics. In contrast, submerged 3D organoid systems are particularly suited for CFTR functional assays, where lumen expansion and ion transport readouts provide quantifiable and standardized endpoints. Inflammatory and remodeling studies occupy an intermediate space, where matrix composition, polarity orientation, and epithelial differentiation state critically influence outcome interpretation. Rather than identifying a universal optimal model, the field may benefit from a stratified methodological framework in which experimental aims guide structural configuration, differentiation strategy, and validation benchmarks. However, such stratification currently lacks standardized criteria and cross-study calibration. Building on this perspective, we propose that future nasal epithelial organoid studies adopt a structured quality framework to enhance reproducibility and translational comparability. Essential reporting domains should include: (i) comprehensive donor metadata, including age, disease status, and genotype where applicable; (ii) detailed expansion and matrix composition protocols; (iii) objective validation of epithelial differentiation through ciliation, mucus production, and barrier integrity assays; (iv) standardized functional benchmarking aligned with experimental aims (e.g., MOI normalization in infection studies, FIS calibration in CFTR assays); and (v) transparent statistical and replication strategies (Figure 5). Such an implementation framework could function either as a reporting checklist or as a benchmarking tool, enabling the field to move from innovation-driven heterogeneity toward structured translational rigor. Limitations This review has several limitations. First, the included studies exhibited substantial methodological heterogeneity in organoid generation, differentiation protocols, and outcome reporting, which precluded quantitative synthesis and meta-analysis. Second, donor metadata were inconsistently reported, limiting assessment of demographic or disease-related variability. Third, most models were based on epithelial monocultures without immune or stromal integration, potentially reducing physiological complexity. Finally, given the rapid evolution of the field, emerging platforms and unpublished protocols may not yet be represented. These limitations should be considered when interpreting the translational generalizability of the findings. The inability to perform quantitative meta-analysis reflects the intrinsic methodological diversity of this rapidly evolving field rather than a limitation of the review design. In experimental domains characterized by heterogeneous protocols and non-uniform endpoints, rigorous qualitative synthesis and identification of standardization gaps may offer greater translational value than premature statistical aggregation. 5. Conclusions Human nasal epithelial organoids have rapidly evolved into versatile and clinically relevant translational platforms. While current methodological heterogeneity limits cross-study comparability, the field is progressively converging toward greater structural and functional standardization. With implementation of shared quality benchmarks and harmonized reporting practices, nasal organoid systems are positioned to become central tools for mechanistic airway research, therapeutic stratification, and precision medicine.